FILTERED RESULTS
FILTERS
Ads Top
DARK MODE
CHART
    Filters
      Symbols
      Sentiment
      Impact
      Search
      FILTERED RESULTS

        

      Upgrade your plan

      Morgan Stanley Raises Price Target for Gilead Sciences

      Morgan Stanley has increased its price target for Gilead Sciences, Inc. to $175, up from a previous target of $171. The investment firm maintains an Overweight rating on Gilead's shares, indicating a positive outlook for the company.

      This adjustment comes as part of Morgan Stanley's updated models across its biopharma coverage, which take into account recent trends from IQVIA and intra-quarter updates. Gilead Sciences is also recognized as one of the 13 NASDAQ stocks with the highest dividends, highlighting its appeal to income-focused investors.

      © 2026 KLEA News. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

      Source: KLEA News

      .

      Terra Founder Do Kwon Sentenced to 15 Years in Prison for Fraud